{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:18:43Z","timestamp":1784344723494,"version":"3.55.0"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Acquired Hemophilia A (AHA) is a rare autoimmune disorder characterized by the onset of a sudden and unexpected bleeding episode in a patient with no personal or family history of bleeding diathesis, and with a typical laboratory feature, i.e., a prolonged activated partial thromboplastin time that is not otherwise explained. This bleeding disorder is caused by autoantibodies directed against the coagulation factor VIII (FVIII). AHA is idiopathic in 50% of cases and is secondary to well-defined diseases in the remaining 50%. AHA affects elderly patients although it has also been observed in the post-partum period. Bleeding manifestations are heterogeneous, ranging from mild to life-threatening bleeds involving limbs and organs. Severe bleeding with a significant decrease in hemoglobin levels must be promptly and adequately treated in order to avoid a worsening of the hemorrhages and their complications. According to international recommendations, the bypass agents (i.e., activated prothrombin complex concentrate and activated recombinant factor VII) and the replacement therapy with recombinant porcine FVIII are considered as the first-line therapy for bleeding control, due to their proven clinical efficacy. Plasma-derived or recombinant FVIII concentrates could be used as second-line treatments. Emicizumab may represent a valid and interesting therapeutic option for prophylaxis of bleeding recurrences.<\/jats:p>","DOI":"10.3390\/medicina59101739","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:55:54Z","timestamp":1695880554000},"page":"1739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies"],"prefix":"10.3390","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-8974","authenticated-orcid":false,"given":"Renato","family":"Marino","sequence":"first","affiliation":[{"name":"Hemophilia and Thrombosis Centre, University Hospital of Bari, Piazza Giulio Cesare 11, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zanon, E. (2023). Acquired Hemophilia A: An update on the etiopathogenesis, diagnosis, and treatment. Diagnostics, 13.","DOI":"10.3390\/diagnostics13030420"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0032-1315757","article-title":"Acquired inhibitors of coagulation factors: Part I\u2014Acquired hemophilia A","volume":"38","author":"Coppola","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.22657","article-title":"Acquired hemophilia in pediatrics: A systematic review","volume":"55","author":"Franchini","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired haemophilia A in the United Kingdom: A 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: Results from the European acquired hemophilia (EACH2) registry","volume":"10","author":"Knoebl","year":"2012","journal-title":"J. Thromb. Hemost."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ajh.20702","article-title":"Postpartum acquired factor VIII inhibitors","volume":"81","author":"Franchini","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_7","first-page":"696","article-title":"Acquired Hemophilia A: Update review of evidence and treatment guidance","volume":"92","author":"Kempton","year":"2017","journal-title":"Am. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"195.e1","DOI":"10.1016\/j.ajem.2013.09.022","article-title":"Acquired factor VIII deficiency presenting with compartment syndrome","volume":"32","author":"Pham","year":"2014","journal-title":"Am. J. Emerg. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia \u2028(EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"ref_12","first-page":"279","article-title":"Bleeding and response to haemostatic therapy in acquired haemophilia A: Results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0002-9629(15)40722-0","article-title":"Acquired hemophilia masked by warfarin therapy","volume":"319","author":"Kantor","year":"2000","journal-title":"Am. J. Med. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to Factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic Prognostic factors for remission of and survival in acquired hemophilia A (AHA): Results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"ref_17","first-page":"245","article-title":"Acquired haemophilia A: Italian Consensus Recommendations on diagnosis, general management and treatment of bleeding","volume":"20","author":"Coppola","year":"2022","journal-title":"Blood Transfus."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2042098611415566","article-title":"Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes","volume":"2","author":"Shapiro","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1111\/hae.13598","article-title":"Retrospective review of acquired haemophilia A from the largest Canadian haemophilia treatment centre","volume":"24","author":"Jayakar","year":"2018","journal-title":"Haemophilia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MBC.0000000000000471","article-title":"Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: Final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study","volume":"27","author":"Ma","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hae.13033","article-title":"Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: Analysis of 10-year Japanese postmarketing surveillance data","volume":"23","author":"Amano","year":"2017","journal-title":"Haemophilia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1055\/s-0039-1678684","article-title":"Eptacog alfa (activated) is physically and chemically stable over 24 h when administer as bolus injections in a automated infusion pump","volume":"3","author":"Rexen","year":"2019","journal-title":"TH Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2516.2003.00856.x","article-title":"Treatment of acquired haemophilia with factor eight inhibitor bypassing activity","volume":"10","author":"Sallah","year":"2004","journal-title":"Haemophilia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.15175","article-title":"Activated Prothrombin Complex Concentrate (FEIBA\u00ae) in Acquired Haemophilia A: A Large Multicentre Italian Study\u2014The FAIR Registry","volume":"184","author":"Zanon","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.thromres.2018.12.006","article-title":"Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to \u2028reduce bleeding relapses: Data from the FAIR registry","volume":"174","author":"Zanon","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2516.2010.02467.x","article-title":"Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors","volume":"17","author":"Gringeri","year":"2011","journal-title":"Haemophilia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: Update of our previous experience","volume":"13","author":"Schneiderman","year":"2007","journal-title":"Haemophilia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2011.08854.x","article-title":"Parallel use of by-passing agents in haemophilia with inhibitors: A critical review","volume":"155","author":"Ingerslev","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and Safety of OBI-1, an Antihaemophilic Factor VIII (Recombinant), Porcine Sequence, in Subjects with Acquired Haemophilia A","volume":"21","author":"Greist","year":"2015","journal-title":"Haemophilia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: Practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/imj.14773","article-title":"Acquired haemophilia and haemostatic control with recombinant porcine FVIII: Case series","volume":"51","author":"Campbell","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_34","first-page":"312","article-title":"Susoctocog-alfa (Obizur\u00ae) in the treatment of nine elderly patients with acquired haemophilia A: An Italian multicentre real-life experience","volume":"18","author":"Zanon","year":"2020","journal-title":"Blood Transfus."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jth.14618","article-title":"Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01\/2010 Study","volume":"18","author":"Klamroth","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_36","first-page":"803","article-title":"Laboratory diagnosis of acquired hemophilia A: Limitations, consequences and challenges","volume":"4","author":"Tiede","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired haemophilia A: Results from the European Acquired haemophilia registry (EACH2)","volume":"1201","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/10245332.2017.1319115","article-title":"Acquired Haemophilia A: A review of recent data and new therapeutic options","volume":"22","author":"Franchini","year":"2017","journal-title":"Hematology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/ejh.13592","article-title":"Principles of care for acquired haemophilia","volume":"106","author":"Dolan","year":"2021","journal-title":"Eur. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: Results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"Dane","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000497287","article-title":"Emicizumab in the treatment of acquired haemophilia: A case report","volume":"46","author":"Pekrul","year":"2019","journal-title":"Transfus. Med. Hemother"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/hae.14664","article-title":"Emicizumab for the treatment of acquired hemophilia A. retrospective review of a single-institution experience","volume":"29","author":"Chen","year":"2023","journal-title":"Haemophilia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: A case report","volume":"20","author":"Alhillan","year":"2019","journal-title":"Am. J. Case Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired haemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20406207211038193","article-title":"Emicizumab in acquired haemophilia A: About two clinical cases and literature review","volume":"12","author":"Hansenne","year":"2021","journal-title":"Ther. Adv. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"key":"ref_48","unstructured":"Shima, M., Amano, K., Ogawa, Y., Yoneyama, K., Ozaki, R., Kobayashi, R., Sakaida, E., Saito, M., Okamura, T., and Ito, T. (2022, January 9\u201313). Efficacy, safety and pharmacokinetics of emicizumab prophylaxis in patients with acquired hemophilia A: Primary analysis results from a phase 3 study (AGEHA). Proceedings of the 30th Congress of International Society on Thrombosis and Haemostasis, London, UK."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2022-162237","article-title":"Efficacy and Safety of Emicizumab Prophylaxis in Patients with Acquired Hemophilia a Who Were Deemed Ineligible for Immunosuppressive Therapy: Additional Data from the Ageha Study [abstract]","volume":"140","author":"Nishiki","year":"2022","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used in patients with acquired hemophilia A?","volume":"19","author":"Tiede","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_51","unstructured":"Pasca, S., Zanon, E., Mannucci, P.M., and Peyvandi, F. (2023). Emicizumab in acquired hemophilia A: Pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus., ahead-of-print."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:42Z","timestamp":1760130042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/10\/1739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["medicina59101739"],"URL":"https:\/\/doi.org\/10.3390\/medicina59101739","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}